Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) (for specialized target groups only)

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents / Bayer to be solely responsible for the global development and commercialization of both larotrectinib and BAY 2731954 (LOXO-195) / Co-Promotion in the U.S. to be converted into exclusive commercialization by Bayer / Larotrectinib was approved in November 2018 in the U.S. under the brand name VITRAKVI ® as the first TRK inhibitor for patients with advanced solid tumors harboring an NTRK gene fusion; filings in Europe and other regions underway
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news